{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:43:06Z","timestamp":1785357786217,"version":"3.55.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Complement-associated disorders are caused by the dysregulation and disbalance of the complement system, especially excessive activation. Most drugs that target the complement system are designed to inhibit the complement pathway at either the proximal or terminal levels. The use of a natural complement regulator such as factor H (FH) could provide a superior treatment option by restoring balance to an overactive complement system. We recently reported the moss-based production of an analog of human FH with an optimized glycan profile (CPV-104), which showed <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> characteristics comparable to its human counterpart. Here, we follow up our previous work, focusing in more detail on the time course and long-term efficacy of CPV-104 treatment in FH-deficient (<jats:italic>FH<\/jats:italic><jats:sup>\u2013\/\u2013<\/jats:sup>) mice. The analysis of long-term treatment effects following multiple injections of human FH into mice was previously hindered by the immune response, so we developed a protocol for the sustained depletion of CD20<jats:sup>+<\/jats:sup> B-cells and CD4<jats:sup>+<\/jats:sup> T-cells, preventing antibody formation without influencing the C3G phenotype. Using this dual-depletion method, we were able to complete dosing interval experiments in <jats:italic>FH<\/jats:italic><jats:sup>\u2013\/\u2013<\/jats:sup> mice, administering up to three injections of CPV-104 at different intervals. Repeated CPV-104 administration was able to lastingly resolve C3 deposits, offering additional rationale for the clinical testing of CPV-104 in human C3G patients. Moreover, our novel dual-depletion method has the potential for adaptation to different mouse models, allowing the testing of multiple doses of other therapeutic proteins.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1535547","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T05:26:23Z","timestamp":1741325183000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Effective long-term treatment with moss-produced factor H by overcoming the antibody response in a mouse model of C3G"],"prefix":"10.3389","volume":"16","author":[{"given":"Todor","family":"Tschongov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swagata","family":"Konwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessika","family":"Kleindienst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Dabrowska-Schlepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"H\u00e4ffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00257","article-title":"Complement system part II: Role in immunity","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2013.08.001","article-title":"Overview of complement activation and regulation","volume":"33","author":"Noris","year":"2013","journal-title":"Semin Nephrol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2010.05.007","article-title":"Complement control protein factor H: the good, the bad, and the inadequate","volume":"47","author":"Ferreira","year":"2010","journal-title":"Mol Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1135490","article-title":"The human factor H protein family \u2013 an update","volume":"15","author":"S\u00e1ndor","year":"2024","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01728","article-title":"Characterization of binding properties of individual functional sites of human complement factor H","volume":"11","author":"Haque","year":"2020","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-071472","article-title":"Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome","volume":"110","author":"J\u00f3zsi","year":"2007","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012037","article-title":"Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification","volume":"138","author":"Mart\u00edn Merinero","year":"2021","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.01.003","article-title":"Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H","volume":"41","author":"S\u00e1nchez-Corral","year":"2004","journal-title":"Mol Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2007.03552.x","article-title":"Translational Mini-Review Series on Complement Factor H: Genetics and disease associations of human complement factor H","volume":"151","author":"De C\u00f3rdoba","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2418-4","article-title":"Complement factor H in host defense and immune evasion","volume":"74","author":"Parente","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.607211","article-title":"Factor H autoantibodies and complement-mediated diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-021-03485-w","article-title":"Complement catalyzing glomerular diseases","volume":"385","author":"Zipfel","year":"2021","journal-title":"Cell Tissue Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110189","article-title":"Complement factor H polymorphism and age-related macular degeneration","volume":"308","author":"Edwards","year":"2005","journal-title":"Sci (New York N.Y.)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501536102","article-title":"A common haplotype in the complement regulatory gene factor H (HF1\/CFH) predisposes individuals to age-related macular degeneration","volume":"102","author":"Hageman","year":"2005","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110359","article-title":"Complement factor H variant increases the risk of age-related macular degeneration","volume":"308","author":"Haines","year":"2005","journal-title":"Sci (New York N.Y.)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Sci (New York N.Y.)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00892-7","article-title":"Tipping the balance: intricate roles of the complement system in disease and therapy","volume":"43","author":"Pouw","year":"2021","journal-title":"Semin Immunopathology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneph.2016.70","article-title":"Complement in disease: a defence system turning offensive","volume":"12","author":"Ricklin","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/J.MOLIMM.2022.08.002","article-title":"From magic bullets to modern therapeutics: Paul Ehrlich, the German immunobiologist and physician coined the term \u201ccomplement.\u201d","volume":"150","author":"Zipfel","year":"2022","journal-title":"Mol Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350816","article-title":"Complement-targeted therapeutics: Are we there yet, or just getting started","volume":"54","author":"Ricklin","year":"2024","journal-title":"Eur J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAUT.2024.103216","article-title":"Balancing efficacy and safety of complement inhibitors","volume":"145","author":"Watanabe-Kusunoki","year":"2024","journal-title":"J Autoimmun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02166","article-title":"Complement inhibitors in clinical trials for glomerular diseases","volume":"10","author":"Zipfel","year":"2019","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.132","article-title":"Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice","volume":"78","author":"Fakhouri","year":"2010","journal-title":"Kidney Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.681098","article-title":"Murine factor H co-produced in yeast with protein disulfide isomerase ameliorated C3 dysregulation in factor H-deficient mice","volume":"12","author":"Kerr","year":"2021","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.03.030","article-title":"Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase","volume":"46","author":"Paix\u00e3o-Cavalcante","year":"2009","journal-title":"Mol Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117751","article-title":"Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency","volume":"95","author":"H\u00f8g\u00e5sen","year":"1995","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt336","article-title":"Genetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degeneration","volume":"22","author":"Ansari","year":"2013","journal-title":"Hum Mol Genet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.660194","article-title":"A family affair: addressing the challenges of factor H and the related proteins","volume":"12","author":"Poppelaars","year":"2021","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/J.1423-0410.2012.01610.X","article-title":"Purification and biochemical characterization of functional complement factor H from human plasma fractions","volume":"103","author":"Brandst\u00e4tter","year":"2012","journal-title":"Vox Sanguinis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/J.PEP.2013.07.014","article-title":"A method of purifying intact complement factor H from human plasma","volume":"91","author":"Wang","year":"2013","journal-title":"Protein Expression Purification"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2024.1334151\/","article-title":"Proof of concept of a new plasma complement Factor H from waste plasma fraction","volume":"15","author":"Mori","year":"2024","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2010.12.002","article-title":"Production of biologically active complement factor H in therapeutically useful quantities","volume":"76","author":"Schmidt","year":"2011","journal-title":"Protein Expression Purification"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2020.00443","article-title":"Mechanisms of FH protection against neovascular AMD","volume":"11","author":"Borras","year":"2020","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(94)90116-3","article-title":"Biologically active recombinant human complement factor H: synthesis and secretion by the baculovirus system","volume":"143","author":"Sharma","year":"1994","journal-title":"Gene"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1383123","article-title":"Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity","volume":"15","author":"Tschongov","year":"2024","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/0471142735.im0401s113","article-title":"In vivo depletion of T lymphocytes","volume":"113","author":"Laky","year":"2016","journal-title":"Curr Protoc Immunol"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.155.12.5663","article-title":"Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1","volume":"155","author":"K\u00fchn","year":"1995","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"178fs10","DOI":"10.1126\/scitranslmed.3005007","article-title":"Protein replacement therapies for rare diseases: A breeze for regulatory approval","volume":"5","author":"Gorzelany","year":"2013","journal-title":"Sci Trans Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3877","article-title":"Advances in targeting cell surface signalling molecules for immune modulation","volume":"12","author":"Yao","year":"2013","journal-title":"Nat Rev Drug Discovery"},{"key":"B42","doi-asserted-by":"publisher","first-page":"925135","DOI":"10.1155\/2012\/925135","article-title":"CD4 + T cells: differentiation and functions","volume":"2012","author":"Luckheeram","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12754","article-title":"The continuing story of T-cell independent antibodies","volume":"288","author":"Allman","year":"2019","journal-title":"Immunol Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2015.12.003","article-title":"Diagnosis of complement alternative pathway disorders","volume":"89","author":"Angioi","year":"2016","journal-title":"Kidney Int"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676662","article-title":"Selective binding of heparin\/heparan sulfate oligosaccharides to factor H and factor H-related proteins: therapeutic potential for C3 glomerulopathies","volume":"12","author":"Loeven","year":"2021","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.02.001","article-title":"C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement","volume":"32","author":"Liu","year":"2024","journal-title":"Mol Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02329","article-title":"Unraveling the molecular mechanisms underlying complement dysregulation by nephritic factors in C3G and IC-MPGN","volume":"9","author":"Donadelli","year":"2018","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1289812","article-title":"C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis","volume":"10","author":"Ponticelli","year":"2023","journal-title":"Front Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017070738","article-title":"The MFHR1 fusion protein is a novel synthetic multitarget complement inhibitor with therapeutic potential","volume":"29","author":"Michelfelder","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.752916","article-title":"Homodimeric minimal factor H: in vivo tracking and extended dosing studies in factor H deficient mice","volume":"12","author":"Kamala","year":"2021","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s42003-022-03094-5","article-title":"A synthetic protein as efficient multitarget regulator against complement over-activation","volume":"5","author":"Ruiz-Molina","year":"2022","journal-title":"Commun Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1535547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T05:26:27Z","timestamp":1741325187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1535547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2025.1535547"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1535547","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"article-number":"1535547"}}